COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04224922
Recruitment Status : Completed
First Posted : January 13, 2020
Last Update Posted : January 18, 2020
Universitaire Ziekenhuizen Leuven
Universitair Ziekenhuis Brussel
Information provided by (Responsible Party):
Dr Fontaine Christel, AZ-VUB

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 2016
Actual Study Completion Date : May 2017